Xceleron and JCL Bioassay will provide access to clinical design expertise and an appropriate analytical platform for the purpose of early clinical investigation.
Both companies have between them developed over 100 analytical methods for Phase 0 and enriched Phase 1 investigations and recently built, equipped and staffed laboratories specifically for the purpose of ultra-low level analyses under GLP and GCP conditions.
Xceleron CEO Dr Michael Butler said, "This partnership emphasizes the critical role of contemporary analytical platforms in driving down the cost of drug development. Whether in Phase 0 or enriched Phase I, we can confidently provide critical PK and PD information before Phase II."
Bioassay operations vice president and CSO Jenny Lin said, "The partnership with Xceleron further expands the geographic and technological scope of the services we can provide to our customers and promotes the use of these cutting-edge analytical platforms to detect low level analytes in early drug development."